Gencurix Demonstrates High Accuracy of Liquid Biopsy 메이저 바카라 사이트 Mutation Test in German Multicenter Study

Droplex 메이저 바카라 사이트 Test shows 96.8% concordance with NGS in breast cancer liquid biopsy study

2025-04-24Sung, Jae Jun
Droplex 메이저 바카라 사이트 Mutation Test v2. (Source: Gencurix)

[by Sung, Jae Jun]Gencurix, a precision diagnostics company, announced on April 24 thatits digital PCR-based Droplex 메이저 바카라 사이트 Mutation Test v2 has demonstrated excellent reliability, achieving a concordance rate of 96.8% when compared with high-sensitivity next-generation sequencing (NGS) technologies in a German multi-center study (Borkar et al., Cancers, 2025).

The study was conducted using data from approximately 6,000 real-world breast cancer cases, including those at Charité University Hospital and the Institute of Hematopathology in Hamburg. Among 354 metastatic breast cancer patients who had received endocrine therapy (ET), 메이저 바카라 사이트 mutations were detected in 43% of liquid biopsy samples, underscoring the clinical relevance of early mutation detection.

In a direct comparison involving 32 patient plasma cfDNA samples, researchers evaluated both the Droplex 메이저 바카라 사이트 Mutation Test and a customized high-sensitivity NGS method for breast cancer. The Droplex assay successfully identified even low-frequency 메이저 바카라 사이트 mutations with a variant allele fraction (VAF) of approximately 0.5%, confirming its sensitivity and reliability.

Liquid biopsy-based testing for 메이저 바카라 사이트 mutations is formally recommended by both the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). Droplex 메이저 바카라 사이트 Mutation Test offers a cost-effective solution, especially in clinical settings where sample volume is limited or frequent monitoring of specific mutations is required. It also serves as a clinically valuable companion diagnostic tool for SERD therapies such as the FDA- and EMA-approved Elacestrant, as well as investigational agents like Camizestrant.

Digital PCR-based liquid biopsy is considered an optimal approach for early mutation detection, offering faster turnaround and lower cost compared to NGS, which typically requires over three weeks. These features make it ideal for repeated testing and real-time monitoring.

As a leader in high-sensitivity digital PCR diagnostics, Gencurix provides robust diagnostic platforms to support precision oncology. The Droplex 메이저 바카라 사이트 Mutation Test has received CE-IVD certification and is currently being used in routine clinical diagnostics across Europe, alongside the Droplex PIK3CA Mutation Test.